You are now leaving the website.

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.


Biosimilar medicines: a complex new entrant

Biosimilar medicines: a complex new entrant

Like their name implies, biosimilars are similar to originator biologics but not identical.

In fact, because biologic and biosimilar medicines are created from living cell lines, no two medicines are ever exactly the same. To make informed choices, patients, doctors, and health care providers should understand the complexity of these drugs.

“As biosimilars are similar but not identical to the innovator drug, they may not behave in the same way. As such, physicians need to be well-informed regarding any therapeutic changes whether between innovator biologics or innovator and biosimilars biologics.” – Dr. Denis Choquette, Rheumatologist and Professor of Medicine from the University of Montreal

Both biologics and biosimilars require high levels of manufacturing expertise, cutting-edge equipment and are evaluated against high standards. These medicines are highly sensitive, and undergo rigorous quality control measures to ensure purity, safety and efficacy of the product.

See the infographic below for a high-level snapshot of the manufacturing process:

Manufacturing Biologics infographic detailing the manufacturing process of biologic medicines

Do you want to link to our other external sites and leave

You are now leaving the Amgen Canada website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.